Corporate Investor : Gian Lim

Preferred Investment Amount	RM500,001 to RM1,000,000
Preferred Investment Opportunity	AI,VR, HEALTHCARE, SOCIAL MEDIA
Will NOT Invest In	LOGISTIC
Preferred Location	Doesn’t Matter
Public Profile	PUBLIC LISTED COMPANY
NAME	GIAN
Organization	MYEG
Address	MYEG TOWER, EMPIRE CITY DAMANSARA

Comments (1)

John Loke
September 3, 2017 Reply

It is my pleasure to introduce exciting startup ; a phyto-science herbal formulation with proven efficacy in treating dengue fever.

( Note: WHO has already classified Dengue Fever as a World Pandemic Disease with yearly recurring 50-100 million dengue cases.)

The formulation should be entering full commercial production subject to usual governmental regulatory compliances,such as Health Ministry.This is not medical product but phyto-science dietary supplement form to circumvent the insurmountable obstacles associated with medical grade product.

I am working with a group of Bumiputras including a influential Malay Dato to smoothen the process of Government Affairs.

The financial modeling indicated a IPO valuation of RM600 Million upward subject to assumptions of RM 30 Million profit.

No doubt all pertinent assumptions and workings of the financial projection report is being finalized and will be shown at later stage of our discussion.

The Business Model with its formulation ownership will be injected into a Special Listing Vehicle ( SLV ) and thereafter shares will be sold-down to investors in stages.

We have entered into a preliminary understanding with RHB Group that they will engage with the proposed SLV for IPO listing in 2 /3 years subject to the requisite results being attained.

The startup phase ( with the Dengue Fever Cure product with us ) is seeking the right complimentary VC Funder to finance the startup operation from setting up te office right up to getting the product registration successfully completed.

2nd round of funding via possibly Government Grant or Crowdfunding will be employed to raise the necessary funding for commercial operation such as marketing and production and professional management team to be put in place.

I do hope that the foregoing Business Brief would have given your kindself an overview of the IPO mission and its investment opportunity at this startup stage.

For enhancing wealth creation to shareholders we have plans to pre-sell strategic share block of the SLV to selected GLC or PLC who will compliment this Dengue Fever business after having secured product registration successfully ( estimated to be around early 2018)